Annals of Hematology

, Volume 98, Issue 3, pp 735–743 | Cite as

Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy

  • Tianhua He
  • Ailin Zhao
  • Hao Zhao
  • Hao Cai
  • Jun Feng
  • Lu Zhang
  • Xinxin Cao
  • Daobin Zhou
  • Jian LiEmail author
Original Article


The diagnosis of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome requires polyneuropathy and monoclonal plasma cell proliferation as two mandatory criteria. Our aim was to summarize clinical manifestations and treatment responses of POEMS variants with no evidence of monoclonal gammopathy. We queried all medical documentation of patients referred to Peking Union Medical College Hospital from August 2012 to July 2017, and reviewed the clinical and laboratory features of 13 patients with atypical POEMS syndrome with undetectable monoclonal gammopathy, and compared to prototypes published. The prevalence of polyneuropathy, organomegaly, skin changes, and extravascular fluid overload were 100%, 100%, 92%, and 100%, respectively. Other clinical manifestations, such as endocrinopathy, pulmonary hypertension, papilledema, thrombocytosis, and polycythemia affected similar percentages of patients as seen in prototypes. POEMS variants enrolled had a median serum vascular endothelial growth factor (VEGF) level of 4998 pg/ml (range 2155–11,029 pg/ml). Long-term follow-up found that all 12 patients received autologous stem cell transplant, melphalan-based therapy or lenalidomide/thalidomide-based therapy obtained clinical improvement, of which eight experienced decreased levels of VEGF by 50% or back to normal. The median progression-free survival was 101.5 months. Our findings raised a variant of POEMS syndrome variants with featured clinical manifestations, elevated VEGF levels, and good response to therapies targeting plasma cell.


POEMS syndrome Vascular endothelial growth factor Monoclonal gammopathy Plasma cell 



We thank all patients and their families. We also thank Lijia Cui for technical support on statistical analysis, and Sarah Cui for polishing the written English language.


This study was funded by National Natural Science Foundation of China (Grant No. 81570195), Peking Union Medical College New Star (2011, to LJ), the CAMS Innovation Fund for Medical Sciences (Grant/Award Number: 2016-12M-1-002), and the National Key Research and Development Program of China (Grant/Award Number: 2016YFC0901503).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA (2003) POEMS syndrome: definitions and long-term outcome. Blood 101(7):2496–2506. CrossRefGoogle Scholar
  2. 2.
    Dispenzieri A (2017) POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92(8):814–829. CrossRefGoogle Scholar
  3. 3.
    D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A (2011) The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 118(17):4663–4665. CrossRefGoogle Scholar
  4. 4.
    Cao X, Wang C, Cai H, Duan M, Zhang W, Li T, Zhou D, Li J (2014) Diagnostic performance and clinical correlation of serum vascular endothelial growth factor levels in patients with newly diagnosed POEMS syndrome. Zhonghua Xue Ye Xue Za Zhi 35(12):1065–1068. Google Scholar
  5. 5.
    Zhao H, Cai H, Wang C, Huang XF, Cao XX, Zhang L, Zhou DB, Li J (2018) Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome. Blood Cancer J 8(4):37. CrossRefGoogle Scholar
  6. 6.
    Li J, Zhou DB (2013) New advances in the diagnosis and treatment of POEMS syndrome. Br J Haematol 161(3):303–315. CrossRefGoogle Scholar
  7. 7.
    Hara D, Akiyama H, Nukui S, Shimizu T, Hoshikawa M, Hasegawa Y (2017) Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: a case report. Medicine (Baltimore) 96(41):e8188. CrossRefGoogle Scholar
  8. 8.
    Al-Mayoof O, Al Sughaiyer H, Abuomar W, Khan M (2017) POEMS syndrome: a rare cause of exudative ascites and chronic peripheral neuropathy. BMJ Case Rep.
  9. 9.
    Liang M, Jiang Z, Lin Z, Chen B, Zou H, Wan W, Liu J (2017) Polyneuropathy as novel initial manifestation in a case of “nonsecretory” POEMS syndrome with Sjogren's syndrome. Case Rep Med 2017:1276759. CrossRefGoogle Scholar
  10. 10.
    Graham RC, Hughes RA (2006) A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 77(8):973–976. CrossRefGoogle Scholar
  11. 11.
    Huang X, Zhang C, Wang C, Cai Q, Cao X, Cai H, Zhang L, Feng J, Zhou D, Li J (2016) Measurement of beta-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilities. Blood Cancer J 6(11):e495. CrossRefGoogle Scholar
  12. 12.
    Li J, Zhou DB, Huang Z, Jiao L, Duan MH, Zhang W, Zhao YQ, Shen T (2011) Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 90(7):819–826. CrossRefGoogle Scholar
  13. 13.
    Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA (2008) Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol 80(5):397–406. CrossRefGoogle Scholar
  14. 14.
    Wang C, Su W, Zhang W, Di Q, Duan MH, Ji W, Cao XX, Zhou DB, Li J (2014) Serum immunoglobulin free light chain and heavy/light chain measurements in POEMS syndrome. Ann Hematol 93(7):1201–1206. CrossRefGoogle Scholar
  15. 15.
    Wang C, Huang XF, Cai QQ, Cao XX, Duan MH, Cai H, Zhou DB, Li J (2017) Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome. Leukemia 31(1):100–106. CrossRefGoogle Scholar
  16. 16.
    Gay-Bellile C, Bengoufa D, Houze P, Le Carrer D, Benlakehal M, Bousquet B, Gourmel B, Le Bricon T (2003) Automated multicapillary electrophoresis for analysis of human serum proteins. Clin Chem 49(11):1909–1915CrossRefGoogle Scholar
  17. 17.
    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548. CrossRefGoogle Scholar
  18. 18.
    Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA (2005) Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51(5):878–881. CrossRefGoogle Scholar
  19. 19.
    Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, Rajkumar SV, Dispenzieri A (2009) Screening panels for detection of monoclonal gammopathies. Clin Chem 55(8):1517–1522. CrossRefGoogle Scholar
  20. 20.
    Minarik J, Scudla V, Bacovsky J, Pika T, Ctvrtlik F, Metelkova I, Myslivecek M (2012) Comparison of imaging methods in POEMS syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156(1):52–57. CrossRefGoogle Scholar
  21. 21.
    Dispenzieri A (2007) POEMS syndrome. Blood Rev 21(6):285–299. CrossRefGoogle Scholar
  22. 22.
    Hineman VL, Phyliky RL, Banks PM (1982) Angiofollicular lymph node hyperplasia and peripheral neuropathy: association with monoclonal gammopathy. Mayo Clin Proc 57(6):379–382Google Scholar
  23. 23.
    Black DA, Forgacs I, Davies DR, Thompson RP (1988) Pseudotumour cerebri in a patient with Castleman's disease. Postgrad Med J 64(749):217–219CrossRefGoogle Scholar
  24. 24.
    Feigert JM, Sweet DL, Coleman M, Variakojis D, Wisch N, Schulman J, Markowitz MH (1990) Multicentric angiofollicular lymph node hyperplasia with peripheral neuropathy, pseudotumor cerebri, IgA dysproteinemia, and thrombocytosis in women. A distinct syndrome. Ann Intern Med 113(5):362–367CrossRefGoogle Scholar
  25. 25.
    Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M (1998) Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 21(11):1390–1397CrossRefGoogle Scholar
  26. 26.
    Scarlato M, Previtali SC, Carpo M, Pareyson D, Briani C, Del Bo R, Nobile-Orazio E, Quattrini A, Comi GP (2005) Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 128(Pt 8):1911–1920. CrossRefGoogle Scholar
  27. 27.
    Chan JK, Fletcher CD, Hicklin GA, Rosai J (1990) Glomeruloid hemangioma. A distinctive cutaneous lesion of multicentric Castleman's disease associated with POEMS syndrome. Am J Surg Pathol 14(11):1036–1046CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology, Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations